Incretin Atlas › Trials › RGT-075 phase 2b
RGT-075 phase 2b
RGT-075 · obesity
Design
- Molecule(s)
- RGT-075
- Population
- obesity
- Phase
- 2b
- Duration
- 36 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RGT-075 180 mg oral | obesity | 36 | — | −10.4 % vs −1.6 % Δ −8.8 pp | −10.4 % vs −1.6 % Δ −8.8 pp | — | — | — | — | — | — | −9.9 vs +0.0 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (1)
- RGT-075 180 mg oral · weight_eff · Abstract, Results
treatment with RGT-075 at 180 mg resulted in a least-square mean percent body-weight reduction of 10.4%
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: RGT-075 phase 2b. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/rgt-075-phase-2b/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.